Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector

Journal of Virology

Volumn 79, Issue 11, 2005, Pages 6772-6780

  Aurisicchio, Luigi ^a   De Tomassi, Amedeo ^a   La Monica, Nicola ^a   Ciliberto, Gennaro ^a   Traboni, Cinzia ^a   Palombo, Fabio ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; RECOMBINANT ALPHA INTERFERON; TETRACYCLINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOIDEA; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HEPATITIS C; HEPATITIS GB VIRUS B; HEPATOMA CELL; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPLICON; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA, RECOMBINANT; FEMALE; FLAVIVIRIDAE INFECTIONS; GB VIRUS B; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HELPER VIRUSES; HEPATITIS C; HEPATITIS, VIRAL, ANIMAL; INTERFERON TYPE I, RECOMBINANT; LIVER; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; REPLICON; SAGUINUS;

ADENOVIRIDAE; HEPATITIS C VIRUS; HEPATITIS GB VIRUS B; MURINAE; PRIMATES; RODENTIA; SAGUINUS; SAGUINUS IMPERATOR;

EID: 18744402480     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.11.6772-6780.2005     Document Type: Article

References (38)

1. Armstrong, J. A. 1981. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol. 78:381-387.
2. Aurisicchio, L., H. Bujard, W. Hillen, R. Cortese, G. Ciliberto, N. La Monica, and F. Palombo. 2001. Regulated and prolonged expression of mIFNα in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Ther. 8:1817-1825.
3. Aurisicchio, L., A. Ceccacci, N. La Monica, F. Palombo, and C. Traboni. 2001. Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery. J. Gene Med. 3:394-402.
4. Aurisicchio, L., P. Delmastro, V. Salucci, O. G. Paz, P. Rovere, G. Ciliberto, N. La Monica, and F. Palombo. 2000. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J. Virol. 74:4816-4823.
5. Baron, U., and H. Bujard. 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 327:401-421.
6. Beames, B., D. Chavez, B. Guerra, L. Notvall, K. M. Brasky, and R. E. Lanford. 2000. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J. Virol. 74:11764-11772.
7. Beames, B., D. Chavez, and R. E. Lanford. 2001. GB virus B as a model for hepatitis C virus. Ilar. J. 42:152-160.
8. Bukh, J., C. L. Apgar, and M. Yanagi. 1999. Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology 262:470-478.
9. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, J. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
10. De Tomassi, A., M. Pizzuti, R. Graziani, A. Sbardellati, S. Altamura, G. Paonessa, and C. Traboni. 2002. Cell clones selected from the Huh7 human hepatoma cell line support efficient replication of a subgenomic GB virus B replicon. J. Virol. 76:7736-7746.
11. De Tomassi, A., M. Pizzuti, and C. Traboni. 2003. Hep3B human hepatoma cells support replication of the wild-type and a 5′-end deletion mutant GB virus B replicon. J. Virol. 77:11875-11881.
12. Favre, D., S. Blouin, V. Bender, N. Provost, R. Spisek, F. Porrot, D. Bohl, F. Marmè, Y. Chérel, A. Salvetti, B. Hurtrel, J. M. Heard, Y. Riviére, and P. Moullier. 2002. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 76:11605-11611.
13. Fiedler, M., F. Rodicker, V. Salucci, M. Lu, L. Aurisicchio, U. Dahmen, L. Jun, O. Dirsch, B. M. Putzer, F. Palombo, and M. Roggendorf. 2004. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-α) and IFN-γ: IFN-α but not IFN-γ reduces woodchuck hepatitis virus replication in chronic infection in vivo. J. Virol. 78:10111-10121.
14. Gossen, M., and H. Bujard 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89:5547-5551.
15. Heremans, H., A. Billiau, and P. De Somer. 1980. Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Infect. Immun. 30:513-522.
16. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
17. Hoofnagle, J. H. 1999. Management of hepatitis C: current and future perspectives. J. Hepatol. 31:264-268.
18. Klein, N. C., and B. A. Cunha. 1995. Tetracyclines. Med. Clin. North Am. 79:789-801.
19. Kochanek, S., G. Schiedner, and C. Volpers. 2001. High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. 3:454-463.
20. Latta-Mahieu, M., M. Rolland, C. Caillet, M. Wang, P. Kennel, I. Mahfouz, I. Loquet, J. F. Dedieu, A. Mahfoudi, E. Trannoy, and V. Thuillier. 2002. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum. Gene Ther. 13:1611-1620.
21. Maione, D., M. Wiznerowicz, P. Delmastro, R. Cortese, G. Ciliberto, N. La Monica, and R. Savino. 2000. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11:859-868.
22. Morral, N., R. J. Parks, H. Zhou, C. Langston, G. Schiedner, J. Quinones, F. L. Graham, S. Kochanek, and A. L. Beaudet 1998. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alphal-antitrypsin with negligible toxicity. Hum. Gene Ther. 9:2709-2716.
23. Muerhoff, A. S., T. P. Leary, J. N. Simons, T. J. Pilot-Matias, G. J. Dawson, J. C. Erker, M. L. Chalmers, G. G. Schlauder, S. M. Desai, and I. K. Mushahwar. 1995. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. J. Virol. 69:5621-5630.
24. National Institutes of Health. 2002. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 36(Suppl. 1):S3-S20.
25. Reichard, O., G. Norkrans, A. Fryden, J. H. Braconier, A. Sonnerborg, O. Weiland, et al. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87.
26. Rosenberg, S. 2001. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 313:451-464.
27. Salucci, V., M. Lu, L. Aurisicchio, N. La Monica, M. Roggendorf, and F. Palombo. 2002. Expression of a new woodchuck IFN-α gene by a helper dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes. J. Interf. Cytok. Res. 22:1027-1034.
28. s-M2 tetracycline transactivator and repressor system. Gene Ther. 9:1415-1421.
29. Sandig, V., R. Youil, A. J. Bett, L. L. Franlin, M. Oshima, D. Maione, F. Wang, M. L. Metzker, R. Savino, and C. T. Caskey. 2000. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. USA 97:1002-1007.
30. Sbardellati, A., E. Scarselli, E. Verschoor, A. De Tomassi, D. Lazzaro, and C. Traboni. 2001. Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins. J. Gen. Virol. 82:2437-2448.
31. Scarselli, E., A. Urbani, A. Sbardellati, L. Tomei, R. De Francesco, and C. Traboni. 1997. GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity. J. Virol. 71:4985-4989.
32. Schiedner, G., N. Morral, R. J. Parks, Y. Wu, S. C. Koopmans, C. Langston, F. L. Graham, A. L. Beaudet, and S. Kochanek. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18:180-183. (Erratum, 18:298.)
33. Simons, J. N., T. J. Pilot-Matias, T. P. Leary, G. J. Dawson, S. M. Desai, G. G. Schlauder, A. S. Muerhoff, J. C. Erker, S. L. Buijk, M. L. Chalmers, et al. 1995. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl. Acad. Sci. USA 92:3401-3405.
34. Snedecor, G. W., and W. G. Cochran. 1980. Statistical methods. Iowa State University Press, Ames, Iowa.
35. Tilg, H. 1997. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112: 1017-1021.
36. Urlinger, S., U. Baron, M. Thellmann, M. T. Hasan, H. Bujard, and W. Hillen. 2000. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA 97:7963-7968.
37. Wills, R. J. 1990. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 19:390-399.
38. Zhong, W., P. Ingravallo, J. Wright-Minogue, A. S. Uss, A. Skelton, E. Ferrari, J. Y. Lau, and Z. Hong. 2000. RNA-dependent RNA polymerase activity encoded by GB virus-B non-structural protein 5B. J. Viral Hepat. 7:335-342.